Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

[Predictive factors of the response to treatment with onabotulinumtoxinA in refractory migraine].

Pagola I, Esteve-Belloch P, Palma JA, Luquin MR, Riverol M, Martinez-Vila E, Irimia P.

Rev Neurol. 2014 Mar 16;58(6):241-6. Spanish.

2.

[Clinical experience of treatment with onabotulinumtoxin A in patients with refractory migraine].

Palma JA, Irimia P, Fernandez-Torron R, Ortega-Cubero S, Riverol M, Luquin MR, Martinez-Vila E.

Rev Neurol. 2012 Jun 16;54(12):705-11. Spanish.

3.

[Botulinum toxin A in chronic refractory migraine: premarketing experience].

Álvaro-González LC, Fernández-García JM, Aranzábal-Alustiza I, Castillo-Calvo B, Iriondo-Etxenagusia I, Rodríguez-Antigüedad A.

Rev Neurol. 2012 Oct 1;55(7):385-91. Spanish.

4.

A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.

Negro A, Curto M, Lionetto L, Martelletti P.

J Headache Pain. 2015;17:1. doi: 10.1186/s10194-016-0591-3.

5.

Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.

Mathew NT, Kailasam J, Meadors L.

Headache. 2008 Feb;48(2):194-200.

PMID:
17868356
6.

Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.

Rothrock JF, Bloudek LM, Houle TT, Andress-Rothrock D, Varon SF.

Headache. 2014 Nov-Dec;54(10):1565-73. doi: 10.1111/head.12456.

7.

Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.

Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R.

Pain. 2006 Dec 5;125(3):286-95.

8.

Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.

Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.

Headache. 2012 Sep;52(8):1219-25. doi: 10.1111/j.1526-4610.2012.02164.x.

PMID:
22607530
9.

Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study.

Lin KH, Chen SP, Fuh JL, Wang YF, Wang SJ.

J Chin Med Assoc. 2014 Jan;77(1):10-5. doi: 10.1016/j.jcma.2013.09.006.

10.

OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine.

Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J.

Pain. 2015 May;156(5):820-4. doi: 10.1097/j.pain.0000000000000119.

PMID:
25735000
11.

Migraine prophylaxis with botulinum toxin A is associated with perception of headache.

Burstein R, Dodick D, Silberstein S.

Toxicon. 2009 Oct;54(5):624-7. doi: 10.1016/j.toxicon.2009.01.009.

12.

Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.

Guerzoni S, Pellesi L, Baraldi C, Pini LA.

J Headache Pain. 2015;17:48. doi: 10.1186/s10194-016-0634-9.

13.

Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?

Cernuda-Morollón E, Ramón C, Larrosa D, Alvarez R, Riesco N, Pascual J.

Cephalalgia. 2015 Sep;35(10):864-8. doi: 10.1177/0333102414561873.

PMID:
25431141
14.

An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.

Cady R, Turner I, Dexter K, Beach ME, Cady R, Durham P.

Headache. 2014 Feb;54(2):269-77. doi: 10.1111/head.12250.

PMID:
24147647
15.

Development of onabotulinumtoxinA for chronic migraine.

Whitcup SM, Turkel CC, DeGryse RE, Brin MF.

Ann N Y Acad Sci. 2014 Nov;1329:67-80. doi: 10.1111/nyas.12488. Review.

16.

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.

Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.

J Neurol Sci. 2013 Aug 15;331(1-2):48-56. doi: 10.1016/j.jns.2013.05.003.

PMID:
23790235
17.

Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.

Lipton RB, Silberstein SD.

Headache. 2015 Mar;55 Suppl 2:103-22; quiz 123-6. doi: 10.1111/head.12505_2. Review.

PMID:
25662743
18.

OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.

Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.

Headache. 2011 Oct;51(9):1358-73. doi: 10.1111/j.1526-4610.2011.01990.x.

PMID:
21883197
19.

The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.

Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, Sansebastiano GE, Torelli P.

Neurol Sci. 2016 Jul;37(7):1127-31. doi: 10.1007/s10072-016-2568-z.

PMID:
27048312
20.

A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Mathew NT, Jaffri SF.

Headache. 2009 Nov-Dec;49(10):1466-78. doi: 10.1111/j.1526-4610.2009.01566.x.

PMID:
19912346
Items per page

Supplemental Content

Support Center